William Blair analyst Ryan Daniels has reiterated their bullish stance on EVH stock, giving a Buy rating on August 1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Daniels has given his Buy rating due to a combination of factors including Evolent Health’s strong adjusted EBITDA performance and favorable trends in their business operations. Despite some setbacks in revenue due to timing issues with client go-lives and customer refunds, the company exceeded expectations in adjusted EBITDA, which came in higher than both the guidance midpoint and market estimates.
Additionally, Evolent Health is experiencing robust client retention and a strong pipeline nearing $1 billion. The company has also secured new revenue agreements, including a significant contract with CVS/Aetna. Management remains optimistic about future growth, maintaining a positive outlook for 2026 with projected sales growth exceeding 30%. These factors contribute to a positive long-term view, justifying the Buy rating.
Daniels covers the Healthcare sector, focusing on stocks such as Addus Homecare, Evolent Health, and Astrana Health. According to TipRanks, Daniels has an average return of 5.6% and a 45.77% success rate on recommended stocks.